Form 4: Indivior Officer Granted RSUs, Performance Units Vest

Indivior Pharmaceuticals' Chief Accounting Officer, Woodrow D. Anderson, reported the grant of restricted stock units and the vesting of performance stock units.

Summary

• Woodrow D. Anderson, Chief Accounting Officer of Indivior Pharmaceuticals, Inc., reported changes in his beneficial ownership.
• Anderson acquired 6,903 shares of Common Stock through a grant of restricted stock units (RSUs) on February 10, 2026, at a price of $0.
• These RSUs will vest in three equal annual installments, beginning on February 10, 2027, contingent on his continued service.
• Anderson also acquired 23,975 Performance Stock Units on February 9, 2026, at a price of $0, which represent a conditional award granted on March 3, 2023.
• The performance conditions for these 23,975 Performance Stock Units were certified on February 9, 2026, and the award is set to vest on March 3, 2026, subject to continued employment.
• Following these transactions, Anderson beneficially owns 11,293 shares of Common Stock and 23,975 Performance Stock Units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing. The successful certification of performance conditions for a significant number of PSUs is a good sign for the company's operational achievements, and the RSU grant reinforces executive alignment.

Positives

• The certification of performance conditions for 23,975 Performance Stock Units indicates that the company met specific targets, which is a positive operational sign.
• The grant of 6,903 Restricted Stock Units aligns the Chief Accounting Officer's interests with long-term shareholder value through future vesting.

Future Outlook

The vesting schedules for the Restricted Stock Units indicate future equity compensation for the Chief Accounting Officer, with the first installment vesting on February 10, 2027. The Performance Stock Units are set to vest on March 3, 2026, subject to continued employment.

Management Comments

• Woodrow D. Anderson granted power of attorney to Jeffrey Burris, Alice Givens, and David Wisniewski to execute and file Section 16(a) forms on his behalf.

Industry Context

StockSavvy.ai notes that executive equity grants and vesting are standard practices in the pharmaceutical industry, aiming to incentivize long-term performance and align management interests with shareholder returns. The certification of performance conditions for the PSUs suggests the company met its internal targets, which can be a positive indicator for operational execution within the competitive pharmaceutical landscape.

Comparison to Industry Standards

• The grant of RSUs and vesting of PSUs are common forms of executive compensation across the pharmaceutical sector, comparable to practices at companies like Pfizer, Johnson & Johnson, and Merck, which frequently use equity awards to retain talent and drive performance.
• The structure of multi-year vesting for RSUs (three equal annual installments) is a standard approach to encourage long-term commitment, similar to plans observed at peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The vesting of performance-based awards suggests the company met certain performance targets, which could be viewed positively. The RSU grant aligns executive incentives with long-term shareholder value.
• Employees (specifically Woodrow D. Anderson): The grants and vesting represent significant equity compensation, incentivizing continued service and performance.

Next Steps

• The 6,903 Restricted Stock Units will begin vesting in three equal annual installments starting February 10, 2027.
• The 23,975 Performance Stock Units are scheduled to vest on March 3, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events (R.S.U. grant and P.S.U. vesting) and does not contain sufficient information to warrant a change in investment recommendation. While the vesting of performance units suggests the company met certain internal targets, this is a backward-looking indicator of past performance rather than a forward-looking catalyst for significant share price movement. A seasoned investor would typically 'hold' based solely on this type of disclosure, awaiting more comprehensive financial or strategic updates.

Keywords

Indivior Pharmaceuticals, INDV, Form 4, Insider Trading, Restricted Stock Units, Performance Stock Units, Executive Compensation, Beneficial Ownership, Chief Accounting Officer